Artivion (AORT) Set to Post Earnings on Thursday

Artivion (NYSE:AORT) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.0612) per share and revenue of $120.97 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. On average, analysts expect Artivion to post $0.45 EPS for the current fiscal year and $0.77 EPS for the next fiscal year.

Artivion Stock Performance

NYSE AORT opened at $22.95 on Thursday. Artivion has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a 50 day moving average of $24.09 and a 200-day moving average of $29.66. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -327.80 and a beta of 1.23.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AORT. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research report on Tuesday, July 21st. Weiss Ratings downgraded shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Canaccord Genuity Group upped their target price on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Finally, Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $42.86.

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 70,000 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 977 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares of the company’s stock, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 90,460 shares of company stock valued at $2,557,366 over the last quarter. Corporate insiders own 6.30% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.